India will get its first major treatment for a rare form of brain cancer in more than 25 years, with the drug regulator clearing Servier India to launch Vorasidenib (Voranigo), a targeted therapy for patients with Grade 2 IDH-mutant glioma.

The Central Drugs Standard Control Organisation (CDSCO) granted approval after the medicine was cleared by the US Food and Drug Administration in August 2024 and by European regulators in September 2025 an unusually quick turnaround for an orphan-disease therapy entering the Indian market. Servier is expected to price the drug lower than its US and European counterparts to support affordability. Advertisement

Servier India, the Indian subsidiary of the France-based healthcare group Servier, said the treatment is approved for patients aged 12 years an

See Full Page